Abstract
PCV3 - Budget Impact Analysis Of Adopting Evolocumab In The Brazilian Private Healthcare System For Patients With Uncontrolled LDL-C And High Cardiovascular Risk
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have